COVID-19-Induced Immune Alterations in Infants
Biomarkers (4)
- LYMPH_PERCENTAGE - Lymphocytes percentage (phv00503731.v1.p1)
- MONO_PERCENTAGE - Monocytes percentage (phv00503732.v1.p1)
- NT_PERCENTAGE - Neutrophils percentage (phv00503730.v1.p1)
- WBC - Whole blood cells percentage (phv00503729.v1.p1)
Demographics (3)
- AGE - Subject age at enrollment (in months) (phv00503705.v1.p1)
- SEX - Self-reported sex (phv00503704.v1.p1)
- SEX - Self-reported sex (phv00503699.v1.p1)
Disease Events (2)
- AFFECTION_STATUS - Healthy or tested positive for Covid (phv00503703.v1.p1)
- FEVER - Presence of fever (phv00503716.v1.p1)
General Health (1)
- LOS - Duration of hospitalization in days (phv00503718.v1.p1)
Imaging (1)
- O2 - Oxygen use (phv00503715.v1.p1)
Medications (3)
- STEROIDS - Use of steroids (phv00503722.v1.p1)
- VACCINES - Vaccination status (phv00503712.v1.p1)
- VASOPRESSORS - Use of vasopressors (phv00503723.v1.p1)
Race and Ethnicity (1)
- RACE_ETHNICITY - Self-reported ethnicity (phv00503706.v1.p1)
Reproductive Health (1)
- GESTATIONAL_AGE - Gestational age of the infant (in weeks) (phv00503710.v1.p1)
Other (20)
- ANALYTE_TYPE - Analyte Type (phv00503726.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00503725.v1.p1)
- CONSENT - Consent group as determined by DAC: Requestor must provide documentation of local IRB approval (phv00503698.v1.p1)
- DAYS_RX_CONTACT_SAMPLE - Days since a known COVID-19 exposure to enrollment (phv00503713.v1.p1)
- DAYS_SX - Days of symptoms at enrollment (phv00503717.v1.p1)
- DELIVERY - Birth delivery method (phv00503711.v1.p1)
- DIAGNOSIS - Diagnosis (phv00503719.v1.p1)
- GROUP - Mild or convalescent, moderate and severe (phv00503707.v1.p1)
- GROUP_DETAILS - Group details (phv00503708.v1.p1)
- HISTOLOGICAL_TYPE - Cell type of sample (phv00503728.v1.p1)
- HOUSEHOLD_MEMBERS - Numbers of members in the household (phv00503714.v1.p1)
- IS_TUMOR - Tumor status (phv00503727.v1.p1)
- SAMPLE_ID - Sample ID (phv00503724.v1.p1)
- SAMPLE_ID - Sample ID (phv00503701.v1.p1)
- SUBJECT_ID - Subject ID (phv00503702.v1.p1)
- SUBJECT_ID - Subject ID (phv00503697.v1.p1)
- SUBJECT_ID - Subject ID (phv00503700.v1.p1)
- TREATMENTS - Medications used for the management of COVID-19 (steroids/antivirals/inotropic...) (phv00503720.v1.p1)
- UNDERLINE_DISEASE - Reported diseases of the pediatric participants (phv00503709.v1.p1)
- VL_NP - Viral loads in nasopharyngeal samples (cycle threshold values) (phv00503721.v1.p1)